Terminated PHASE1 INTERVENTIONAL 2-arm NCT01561950

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

Use of Recombinant FVIIa to Mitigate Clopidogrel Anti-platelet Therapy-Mediated Bleeding in a Single Centre, Randomized, Placebo-controlled, Double-blind Clinical Trial

Sponsor: Novo Nordisk A/S

Conditions Haemostasis Healthy

Interventions clopidogrel eptacog alfa (activated) placebo

Updated 7 times since 2017 Last updated: Nov 22, 2016 Started: May 31, 2008 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from Novo Nordisk A/S

See all terminations from Novo Nordisk A/S

This PHASE1 trial investigates Haemostasis and Healthy and is currently terminated or withdrawn. Novo Nordisk A/S leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE1
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Neptune City, United States